指南目标值：不同风险分层的 LDL-C 目标
为什么"目标值"因人而异
在上一课，我们学过医生会先给你做风险分层 Risk stratification风险分层 · Risk stratification/rɪsk ˌstrætɪfɪˈkeɪʃən/把人群按估算出的总体心血管风险高低分成若干等级（如低危、中危、高危、极高危）的过程；不同层级对应不同的管理目标与干预强度。The process of sorting people into levels according to their estimated total cardiovascular risk (e.g. low, moderate, high, very-high); each level guides different management goals and treatment intensity.🧩 词根拆解 / word rootsrisk风险 · risk＋strat-层、分层 · layer拉丁语 stratum 铺层＋-ification使成为…的过程 · process of making into拉丁语 -ificatio——把人按未来发生动脉粥样硬化性心血管疾病(ASCVD) ASCVD动脉粥样硬化性心血管疾病 · Atherosclerotic cardiovascular diseaseASCVD/ˌæθəroʊskləˈrɒtɪk ˌkɑːrdioʊˈvæskjələr/由动脉粥样硬化引起的一类疾病的总称，包括冠心病、缺血性卒中、外周动脉疾病等。An umbrella term for diseases caused by atherosclerosis, including coronary heart disease, ischaemic stroke, and peripheral artery disease. 的总体风险，分成低危、中危、高危、极高危等层级 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455。分层不是为了贴标签，而是为了回答一个具体问题：你的低密度脂蛋白胆固醇(LDL-C) LDL低密度脂蛋白 · Low-density lipoproteinLDL/ˌloʊ ˈdɛnsɪti ˌlaɪpoʊˈproʊtiːn/运输胆固醇进入外周组织的脂蛋白颗粒；其携带的胆固醇称 LDL-C，是动脉粥样硬化的核心致病因素，俗称“坏胆固醇”。The lipoprotein particle that carries cholesterol to peripheral tissues; its cholesterol cargo (LDL-C) is a central causal driver of atherosclerosis, popularly called 'bad cholesterol'.🧩 词根拆解 / word rootslow-density低密度 · low density＋lipo-脂、脂肪 · fat希腊语 lipos 脂肪＋protein蛋白质 · protein希腊语 prōtos 第一/首要 应该降到多低？
各大指南 给出的答案高度一致：风险越高，LDL-C 目标值 LDL-C goalLDL-C 目标值（治疗目标） · LDL-C treatment goal (target)LDL-C goal/ˌɛl diː ˈsiː ˈtriːtmənt ɡoʊl/指南为某一风险层级设定的、治疗后应达到的低密度脂蛋白胆固醇(LDL-C)水平；风险越高，目标值越低。 对最高风险人群，指南通常采用"绝对目标值 + 较基线下降≥50%"的双重标准，两条都要满足。The low-density-lipoprotein-cholesterol (LDL-C) level a guideline sets as the on-treatment goal for a given risk tier; the higher the risk, the lower the goal. For the highest-risk groups guidelines commonly apply a dual criterion — an absolute goal PLUS a ≥50% reduction from baseline — both of which must be met.🧩 词根拆解 / word rootsLDL-C低密度脂蛋白胆固醇 · low-density lipoprotein cholesterol＋target/goal目标、达标值 · the level aimed for古法语 targe 小盾牌 / 中古英语 gol 边界 越低。这是因为 LDL-C 是动脉粥样硬化的核心致病因素，降得越低、心血管事件越少，而高风险的人从更强的降脂中获益也越大 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455。下面我们把两部主流指南的具体数字摆出来。
图 · 风险越高，LDL-C 目标越低：低危低于 3.0、中危低于 2.6、高危低于 1.8（且降≥50%）、极高危低于 1.4 mmol/L（且降≥50%）。[1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455
2019 ESC/EAS 指南的 LDL-C 目标
欧洲心脏病学会与欧洲动脉粥样硬化学会（ESC/EAS）2019 版血脂异常管理指南，按四个风险层级设定 LDL-C 目标，并为高危及以上人群叠加"较基线下降≥50%"的要求 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455：
| 风险层级 | LDL-C 目标 | 是否要求较基线下降 |
|---|---|---|
| 极高危 (very-high risk) | 低于 1.4 mmol/L（55 mg/dL） | 且下降 ≥50% |
| 高危 (high risk) | 低于 1.8 mmol/L（70 mg/dL） | 且下降 ≥50% |
| 中危 (moderate risk) | 低于 2.6 mmol/L（100 mg/dL） | — |
| 低危 (low risk) | 低于 3.0 mmol/L（116 mg/dL） | — |
对极高危与高危人群，指南同时给出 非-HDL 胆固醇(non-HDL-C) non-HDL-C非高密度脂蛋白胆固醇 · Non-HDL cholesterolnon-HDL-C/nɒn ˌeɪtʃ diː ˈɛl kəˈlɛstərɒl/用总胆固醇减去 HDL 胆固醇算得（非-HDL-C = TC − HDL-C），代表除 HDL 外所有含 apoB 的致动脉粥样硬化脂蛋白（LDL、VLDL 等）所携带的胆固醇总量。Calculated as total cholesterol minus HDL cholesterol (non-HDL-C = TC − HDL-C); it represents the cholesterol carried by all atherogenic apoB-containing lipoproteins (LDL, VLDL, etc.) other than HDL.🧩 词根拆解 / word rootsnon-非、不是 · not拉丁语 non 不＋HDL高密度脂蛋白 · high-density lipoprotein＋chole-胆汁 · bile希腊语 kholē 胆汁＋stere(o)-固体、坚硬 · solid/stiff希腊语 stereos 固体＋-ol醇（化学后缀） · an alcohol (chemistry) 作为次要目标：极高危低于 2.2 mmol/L（85 mg/dL），高危低于 2.6 mmol/L（100 mg/dL），中危低于 3.4 mmol/L（130 mg/dL）[1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455。non-HDL-C 把 LDL 以外所有含载脂蛋白B(apoB) apoB载脂蛋白B · Apolipoprotein BapoB/ˌæpoʊˌlaɪpoʊˈproʊtiːn biː/每个致动脉粥样硬化脂蛋白颗粒(LDL、VLDL、Lp(a)等)上各携带一个的结构蛋白；apoB 浓度反映致病颗粒总数，是比 LDL-C 更直接的风险指标。The structural protein present as exactly one copy per atherogenic lipoprotein particle (LDL, VLDL, Lp(a), etc.); apoB concentration reflects the total number of atherogenic particles and is a more direct risk marker than LDL-C.🧩 词根拆解 / word rootsapo-载（脱辅基蛋白）、来自/衍生 · the protein moiety; from/derived希腊语 apo 离开/由…而来＋lipo-脂、脂肪 · fat希腊语 lipos 脂肪＋protein蛋白质 · protein＋BB 型（区分 apoA、apoE 等） · class B 的致病颗粒也一并纳入，通常在 LDL-C 目标之上加约 0.8 mmol/L [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455。
提示：下降≥50% 和绝对目标值是"两条都要满足"的双重标准，而不是二选一。举例来说，一个极高危患者若基线 LDL-C 为 2.6 mmol/L，即使降了一半到 1.3 mmol/L 达到了低于 1.4 的绝对目标，两条恰好都满足；但若基线本来就偏低，只降到低于 1.4 却不足 50%，指南仍认为未完全达标 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455。
《中国血脂管理指南（2023）》的 LDL-C 目标
中国 2023 版指南在最高风险端进一步细分出"超高危"，其 LDL-C 目标如下 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934：
| 风险层级 | LDL-C 目标 | 是否要求较基线下降 |
|---|---|---|
| 超高危 (ultra-high risk) | 低于 1.4 mmol/L | 且下降 ≥50% |
| 极高危 (very-high risk) | 低于 1.8 mmol/L | 且下降 ≥50% |
| 中危 / 高危 (moderate / high risk) | 低于 2.6 mmol/L | — |
| 低危 (low risk) | 低于 3.4 mmol/L | — |
中国指南同样设有 non-HDL-C 次要目标，其算法很直接：non-HDL-C 目标 = 对应的 LDL-C 目标 + 0.8 mmol/L [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。也就是说，超高危的 non-HDL-C 目标为低于 2.2 mmol/L，极高危为低于 2.6 mmol/L，依此类推 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
两部指南怎么对照着看
命名不完全一样，但方向完全一致——越高危，目标越低。要注意的是层级"名字"和"数字"的对应关系在两部指南间有平移 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934：
- 数值 1.4 mmol/L：在 ESC/EAS 里对应"极高危"，在中国指南里对应"超高危" [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
- 数值 1.8 mmol/L：在 ESC/EAS 里对应"高危"，在中国指南里对应"极高危" [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
- 两部指南在最高两档都采用了**"绝对目标值 + 下降≥50%"的双重标准** [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
- 低危目标略有差异：ESC/EAS 为低于 3.0 mmol/L，中国指南为低于 3.4 mmol/L [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
因此，真正决定你目标值的不是某一个数字，而是你落在哪个风险层级。这也是为什么像脂蛋白(a)(Lp(a)) Lp(a)脂蛋白(a) · Lipoprotein(a)Lp(a)/ˌlaɪpoʊˈproʊtiːn eɪ/一种低密度脂蛋白(LDL)样颗粒，额外通过二硫键连接一个 apolipoprotein(a) 蛋白；血浆水平主要由遗传决定，一生中相对稳定。An LDL-like particle that additionally carries one apolipoprotein(a) molecule bound by a disulfide bond; plasma level is largely genetically determined and stable through life.🧩 词根拆解 / word rootslipo-脂、脂肪 · fat希腊语 lipos 脂肪＋protein蛋白质 · protein希腊语 prōtos 第一/首要＋(a)载脂蛋白(a) 亚型标记 · the apo(a) variant由 LPA 基因编码 这样的风险增强因素 Risk-enhancing factor风险增强因素 · Risk-enhancing factor/rɪsk ɪnˈhɑːnsɪŋ ˈfæktər/标准风险评分未充分覆盖、但会在基础评分之上 把一个人的估算风险向上调整的额外指标（如脂蛋白(a)、载脂蛋白B 等）；常用于把处于边缘或中危的人重新归入更高层级。An additional marker not fully captured by the standard risk score that, on top of the base estimate, pushes a person's estimated risk upward (e.g. lipoprotein(a), apolipoprotein B); often used to reclassify borderline or intermediate individuals into a higher category.🧩 词根拆解 / word rootsrisk风险 · risk＋enhanc-增强、提高 · to increase/strengthen古法语 enhaucier 抬高＋-ing…的（分词/形容词后缀） · participle/adjective suffix＋factor因素 · factor拉丁语 factor 做事者 很重要：它们可能把你从一个层级上调到更高层级，从而把你的 LDL-C 目标进一步压低 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
关于本课未纳入的指南：2018 年 AHA/ACC 胆固醇管理指南也是权威 Tier-1 来源，但其全文在本次撰写时无法被独立打开核对，为遵守"不凭记忆引用"的原则，本课暂不列出其具体数值。
一句话记住
风险分层决定目标值：高风险的人，LDL-C 要降得更低；对最高风险人群，既要达到很低的绝对值，又要较自己的基线至少减半 [1]Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020doi:10.1093/eurheartj/ehz455 [2]Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology 2023doi:10.3389/fphar.2023.1190934。
⚕️ 本内容仅供健康科普与学习，目标值因人而异，请以主治医生和最新指南为准。
参考文献 / References
- Tier 1Mach, Francois et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2020) · doi:10.1093/eurheartj/ehz455
- Tier 1Joint Committee for the Development of Chinese Guidelines for the Management of Blood Lipids et al. 2023 Chinese guideline for lipid management (English full text). Frontiers in Pharmacology (2023) · doi:10.3389/fphar.2023.1190934